Ashwagandha for Stress and Fatigue: What a Rigorous 12-Week Trial Actually Found
Summary
If you've seen ashwagandha marketed as a cure-all for stress, this study is a useful reality check. Researchers in Australia ran a well-designed, 12-week, randomized, double-blind, placebo-controlled trial in 120 overweight or mildly obese adults (ages 40–75) who reported both high stress and fatigue — a population that mirrors a lot of real-world supplement buyers, not just young, healthy volunteers. Participants took either 400 mg/day of a standardized ashwagandha root extract (Witholytin®, 1.5% withanolides, split into two 200 mg doses) or an identical placebo capsule.
The headline result is not what marketing claims usually suggest: on the study's primary outcome — perceived stress, measured with the well-validated Perceived Stress Scale (PSS) — ashwagandha did not beat placebo. Both groups improved substantially (about 39% vs. 36% reduction in stress scores), and the difference between them was not statistically significant (p = 0.867). That's a strikingly large placebo response, and the authors note it contrasts with earlier Indian trials where ashwagandha clearly beat a nearly flat placebo curve — a reminder that context, expectations, and even country of study can shape how "effective" a supplement looks.
Where ashwagandha did separate from placebo was on secondary measures. Self-reported fatigue (Chalder Fatigue Scale) dropped significantly more in the ashwagandha group (46% vs. 31% reduction, p = 0.016). Heart rate variability (RMSSD, a marker of parasympathetic "rest and digest" nervous system activity) rose non-significantly with ashwagandha but fell significantly in the placebo group, producing a significant between-group difference (p = 0.003) — suggesting a physiological, not just subjective, shift. In men, ashwagandha significantly raised free testosterone (+13%, p = 0.048) and luteinizing hormone (p = 0.016) relative to placebo, though levels stayed within normal ranges throughout. In women, estradiol rose 60% in the ashwagandha group versus a slight decline with placebo, though this didn't reach statistical significance (p = 0.137) — an exploratory subgroup hinted the effect might be concentrated in perimenopausal women. Other measures — general physical/mental wellbeing (PROMIS-29), sexual interest, blood glucose, HbA1c, total testosterone, DHEA-S, grip strength, and body measurements — showed no meaningful differences between groups.
Safety-wise, the extract was well tolerated: no serious adverse events, similar side-effect rates to placebo, and no concerning changes in liver, kidney, or blood count markers over 12 weeks.
Bottom line: this trial doesn't support "ashwagandha crushes your perceived stress" claims, but it does add credible evidence for anti-fatigue and autonomic nervous system effects, plus intriguing (preliminary) hormonal signals worth watching.
Sources: Verdure Sciences summary, Full study, PMC, 2025 meta-analysis: cortisol down, perceived stress not significant, 2024 systematic review on stress/anxiety
What This Means For You
For supplement shoppers: This trial used a specific, standardized extract (Witholytin®, hydroalcoholic, 1.5% withanolides) at 400 mg/day split into two doses — not a generic "ashwagandha" capsule of unknown potency. When buying, look for a standardized withanolide percentage on the label and a named, trademarked extract with published research (KSM-66, Sensoril, and Witholytin are the most-studied). Random bulk-powder capsules with no standardization may not replicate these results. Twice-daily dosing (morning and evening, with or without food) matches how this trial dosed it; effects took the full 12 weeks to fully manifest, so don't expect results in days.
Who might benefit most: People struggling more with fatigue/low energy and autonomic dysregulation (poor stress recovery, as reflected in HRV) than with subjective "feeling stressed" may see more benefit than those hoping specifically for a stress-score drop — this trial's stress benefit was matched by placebo.
For men interested in testosterone/vitality: The free testosterone and LH increases are notable but modest, stayed within normal physiological ranges, and were a secondary, exploratory finding — not grounds to expect dramatic strength, libido, or muscle-building effects. Sexual interest scores didn't improve significantly.
For women, especially perimenopausal: The estradiol increase is intriguing but underpowered and not statistically significant overall; it shouldn't be treated as a menopause therapy substitute.
Fitness angle: Grip strength and body composition markers (BMI, waist circumference) didn't change, so don't expect direct performance or physique effects from this dose/duration alone.
Cost-benefit: Ashwagandha is inexpensive and generally well-tolerated, so the risk of trying it for fatigue/recovery support is low — but temper stress-relief expectations against a strong placebo effect.
Important Considerations
This trial was well-designed (Jadad score 5/5: proper randomization, double-blinding, and dropout reporting), but several limits matter. The sample was narrow: overweight/mildly obese adults aged 40–75 with pre-existing stress and fatigue — results may not generalize to lean, young, or non-stressed individuals seeking "extra" benefits. Blood hormone analyses were split by sex, leaving only ~55–60 people per subgroup, which is underpowered to detect anything but large effects — several "trend" findings (MDA, estradiol) could be false negatives, false positives, or both, and should be treated as hypothesis-generating, not confirmatory.
The primary outcome (perceived stress) was negative — ashwagandha did not beat placebo here, despite what some marketing summaries emphasize about the fatigue and hormone findings. The unusually large placebo response (35% stress reduction) is itself a finding that deserves attention: expectancy effects, extensive questionnaire contact, and lifestyle attention during a 12-week trial can meaningfully reduce perceived stress independent of any active ingredient.
The study was funded by Verdure Sciences, the extract's manufacturer, and two of three authors have financial/professional ties to nutraceutical-industry research — a common but relevant conflict of interest in supplement trials. The MDA (oxidative stress) increase in men was unexpected and had high variability; it needs replication before concluding anything about pro-oxidant risk. Longer-term safety beyond 12 weeks, interactions with medications (thyroid, diabetes, psychiatric drugs were exclusion criteria here), and effects in pregnant/breastfeeding people remain unstudied. As always, talk to a doctor before starting ashwagandha if you're on thyroid medication, immunosuppressants, sedatives, or have liver conditions, given ashwagandha's documented effects on thyroid hormones and rare case reports of liver injury in the broader literature.
Terms Explained
Technical Study Details
Study Design
Total Score
JADAD Quality Assessment評価詳細
Randomization
2 / 2Blinding
2 / 2Dropouts/Withdrawals
1 / 1Study Population
- Healthy males and females aged 40-75 years
- Experiencing low energy/fatigue, based on a score of 9 or more on the PROMIS-29 fatigue subscale
- Moderate-to-high stress, based on a score of 14 or higher on the Perceived Stress Scale (PSS)
- Non-smoker
- Body mass index (BMI) between 25 and 35 kg/m2
- No plan to change diet or start new treatments during the study period
- Willing to comply with all study procedures
Interventions
Ashwagandha root extract (Witholytin®)
TreatmentPlacebo
ControlOutcomes
| Outcome | Type | Effect | p-value |
|---|---|---|---|
| Self-reported adverse events | Secondary | - | - |
| Perceived Stress Scale (PSS) total score | Primary | - | p = 0.867 |
| Chalder Fatigue Scale (CFS) total score | Secondary | - | p = 0.016Significant |
| PROMIS-29 Physical Health score | Secondary | - | p = 0.642 |
| PROMIS-29 Mental Health score | Secondary | - | p = 0.626 |
| PROMIS-29 Interest in Sexual Activity subscale score | Secondary | - | p = 0.747 |
| Total testosterone (TT) | Secondary | - | - |
| Free testosterone (FT) | Secondary | - | p = 0.048Significant |
| Estradiol | Secondary | - | p = 0.137 |
| Luteinizing hormone (LH) | Secondary | - | p = 0.016 (Results section); abstract reports p = 0.002 for this comparisonSignificant |
| Dehydroepiandrosterone sulphate (DHEA-S) | Secondary | - | - |
| Malondialdehyde (MDA) | Secondary | - | p = 0.057 |
| Fasting glucose | Secondary | - | - |
| Glycated hemoglobin (HbA1c) | Secondary | - | - |
| Heart Rate Variability (RMSSD) | Secondary | - | p = 0.003Significant |
| Grip strength | Secondary | - | - |
| Body mass index (BMI) | Secondary | - | - |
| Waist circumference (WC) | Secondary | - | - |
| Waist-to-hip ratio (WHR) | Secondary | - | - |
Safety
Conclusion
Supplementing with 200 mg of ashwagandha extract (Witholytin®) twice daily for 12 weeks in overweight/mildly obese, high-stress, fatigued adults aged 40-75 was associated with significant reductions in perceived stress over time, but this reduction (PSS, primary outcome) was not significantly different from placebo (p=0.867). Secondary/exploratory outcomes showed ashwagandha significantly reduced self-reported fatigue (CFS, p=0.016) and increased heart rate variability (RMSSD, p=0.003) compared to placebo. In men, ashwagandha significantly increased free testosterone (p=0.048) and luteinizing hormone (p=0.016) versus placebo. No significant between-group differences were found for other self-report measures (PROMIS-29 physical/mental/sexual interest), DHEA-S, total testosterone, HbA1c, fasting glucose, or grip strength. Ashwagandha was well tolerated with no serious adverse events and no significant changes in safety blood markers or anthropometrics. Findings are preliminary and require confirmation in larger, adequately powered trials.Limitations
- Blood results were analyzed separately by sex, leaving only 60 men and 60 women, making the study underpowered to detect all but large treatment effects
- Measurement frequency could have been improved by adding a midway (e.g., week 6) assessment
- Only a limited number of biological markers were examined; future studies should include additional oxidative stress markers (e.g., myeloperoxidase, total antioxidant capacity) and inflammatory markers (e.g., CRP, TNF-alpha, IL-6)
- Only indirect measures of HPA axis activation were used; future studies should include hair cortisol, diurnal salivary cortisol, cortisol awakening response, or experimental stress procedures (e.g., Maastricht Acute Stress Test)
- Substantial variability in MDA concentrations at week 12 in the ashwagandha group means the MDA finding should be interpreted cautiously